The ecology of cancer from an evolutionary game theory perspective

Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance

(2013) J. N. Farr et al.   BLOOD

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

(2013) G. J. Morgan et al.   CLINICAL CANCER RESEARCH

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Symmetric vs. Asymmetric Stem Cell Divisions: An Adaptation against Cancer?

(2013) Leili Shahriyari et al.   PLoS One

A bottom-up institutional approach to cooperative governance of risky commons

(2013) Vítor V. Vasconcelos et al.   Nature Climate Change

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

(2012) S. K. Kumar et al.   BLOOD

Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1  levels in patients with MGUS

(2011) A. C. Ng et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Explaining the in vitro and in vivo differences in leukemia therapy

(2011) Tom Lenaerts et al.   CELL CYCLE

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Risk of collective failure provides an escape from the tragedy of the commons

(2011) F. C. Santos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic mutations and the hierarchy of hematopoiesis

(2010) Arne Traulsen et al.   BIOESSAYS

Reproductive fitness advantage of BCR–ABL expressing leukemia cells

(2010) Arne Traulsen et al.   CANCER LETTERS

Immunological and Inflammatory Functions of the Interleukin-1 Family

(2009) Charles A. Dinarello   Annual Review of Immunology

Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells

(2009) D Dingli et al.   BRITISH JOURNAL OF CANCER

Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

(2009) T. Lenaerts et al.   HAEMATOLOGICA

Targeting the Pathogenic Role of Interleukin 1β in the Progression of Smoldering/Indolent Myeloma to Active Disease

(2009) Charles A. Dinarello   MAYO CLINIC PROCEEDINGS

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

(2009) John A. Lust et al.   MAYO CLINIC PROCEEDINGS

The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo

(2009) Benedetta Peruzzi et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

(2007) Ya-Wei Qiang et al.   BONE